Cancer Statistics, 2021.

CA A Cancer J Clin. 71: 7-33

Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.

Jpn J Clin Oncol. 51: 28-36

Treatment of Stage III Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Chest. 143: e314S-e340S

AJCC cancer staging manual.

8th Ed. Springer, New York

Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer.

N Engl J Med. 373: 123-135

Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer.

N Engl J Med. 373: 1627-1639

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Lancet. 393: 1819-1830

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Lancet. 387: 1540-1550

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC.

N Engl J Med. 383: 1328-1339

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

N Engl J Med. 382: 41-50

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer.

N Engl J Med. 377: 1919-1929

Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.

N Engl J Med. 379: 2342-2350

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

Lancet. 398: 1344-1357

Felip, E., Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC, in World Conference on Lung Cancer. 2022: Vienna, Austria.

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

Lancet Oncol. 23: 1274-1286

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

Cancer Res. 64: 8919-8923

Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario.

Int J Mol Sci. 20: 1431

EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first-or third-generation TKIs.

Clin Cancer Res. 21: 5305-5313

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer.

N Engl J Med. 383: 1711-1723

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA.

Ann Oncol. 33: S1413-S1414

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N Engl J Med. 386: 1973-1985Provencio-Pulla M. et al.

Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.

J Clin Oncol. 40: 8501

PL03.12 Progression Free Survival and Overall Survival in NADIM II Study.

J Thorac Oncol. 17: S2-S3

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial.

J Clin Oncol. 39: 8511Bryan D.S. Donington J.S.

The role of surgery in management of locally advanced non-small cell lung cancer.

Curr Treat Options Oncol. 20: 1-13

Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection.

J Thorac Oncol. 7: 365-369

Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung.

Int J Radiat Oncol Biol Phys. 84: 456-463

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Lancet. 374: 379-386

Impact of teaching facility status and high-volume centers on outcomes for lung cancer resection: an examination of 13,469 surgical patients.

Ann Surg Oncol. 16: 3-13

An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non–small cell lung cancer.

J Thorac Cardiovasc Surg. 143: 55-63

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

J Clin Oncol. 39: 8503

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Cancer Discov. 6: 1382-1399

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Nat Med. 24: 1655-1661

Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care.

Ann Surg Oncol. 29: 5344-5346

LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801).

Ann Oncol. 33: S1408

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.

Lancet. 386: 1049-1056

A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).

Cancer. 118: 6126-6135

Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis.

World J Surg Oncol. 16: 8

Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.

Int J Radiat Oncol Biol Phys. 75: 1462-1467

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.

Lancet Oncol. 22: 824-835